На главнуюФильмы и анимацияПохожее видеоЕще от: ecancer

New treatment options in metastatic prostate cancer

Оценок: 48 | Просмотров: 10905
Dr Shore (Carolina Urologic Research Center, Myrtle Beach, USA) and Dr Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) discuss new treatment options for metastatic prostate cancer for ecancertv at ASCO GU 2016. They discuss an open-label phase II study which evaluated the efficacy of concurrent administration of radium Ra 223 dichloride (Ra-223) and abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases. They also consider a new option arising for those CRPC patients who have become resistant to abiraterone and enzalutamide - the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist VT-464. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Категория: Фильмы и анимация
Html code for embedding videos on your blog
Текстовые комментарии (4)
Arun Bharti (19 дней назад)
sir can enzulatamide be given in Metastatic CRPC if abiatarone is already given and psa still rise.
Dikster trikster (2 месяца назад)
Can anyone tell me what language they are speaking? at first it sounds like english but quickly slips into urologist speak, completely foreign to most people.
ecancer (2 месяца назад)
This talk is targeted for physicians and healthcare professionals, however we make it public for members of the general public to watch if they are interested. It is important for information to be communicated on a variety of levels, this includes language that would be most understandable to doctors. This ensures the doctors can treat patients in the best way possible. We also offer e-learning and have a website dedicated to patient information and patient care.
Martin Gugino (2 года назад)
VT464 trial at 7 minutes. then arv9 and arv9

Хотите оставить комментарий?

Присоединитесь к YouTube, или войдите, если вы уже зарегистрированы.